Search

everythinglearnresearchcommunity

for

Search:↓

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Belimumab effectively controls SLE disease activity and reduces steroid use.

The document did not conclude on apremilast's effectiveness for severe alopecia areata.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.

JAK inhibitors may help improve symptoms in adults with APECED.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Ocrelizumab may cause pancreatitis in some patients.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Baricitinib may help people with long-term alopecia areata.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

New retinoids are effective for various skin conditions and are being developed to have fewer side effects.

Etanercept may cause lichen planopilaris, so doctors should be cautious.

Acitretin moderately improved skin and eye issues but not hair loss or light sensitivity in a 3-year-old with IFAP syndrome.

A woman developed psoriasis after taking certolizumab pegol, improving after stopping the drug and starting other treatments.

Alefacept may effectively treat severe lichen planus, with patients showing significant improvement and no side effects.

Baricitinib significantly regrows hair in teens with severe alopecia areata.